# Xenon Pharmaceuticals (XENE) - Azetukalner Analysis
## Comprehensive Financial Model & M&A Assessment

**Prepared:** December 7, 2025
**Analyst Review Package**
**Data Source:** Google Finance, SEC Filings, Company Reports

---

## Executive Summary

| Metric | Value |
|--------|-------|
| **Ticker** | XENE (NASDAQ) |
| **Market Cap** | $3.48B |
| **Stock Price** | $45.01 |
| **Shares Outstanding** | 77.3M |
| **Cash Position** | $691.1M |
| **Cash Runway** | Into 2027 |
| **Lead Asset** | Azetukalner (XEN1101) |
| **Stage** | Phase 3 |
| **M&A Score** | 81/100 |
| **Deal Probability (24mo)** | 55% |
| **Estimated Deal Value** | $5.2B - $12B |

---

## 1. Azetukalner (XEN1101) Overview

### Mechanism of Action
- **Class:** Kv7 Potassium Channel Opener
- **Differentiation:** First-in-class, novel mechanism vs traditional sodium channel AEDs
- **Dosing:** Once daily oral

### Clinical Development Status

| Indication | Trial | Stage | Patients | Data Readout |
|------------|-------|-------|----------|--------------|
| Focal Onset Seizures | X-TOLE2 | Phase 3 | 360 | Q1 2026 |
| Focal Onset Seizures | X-TOLE3 | Phase 3 | 360 | Q2 2026 |
| PGTCS | X-ACKT | Phase 3 | ~300 | 2026 |
| Major Depression | X-NOVA3 | Phase 3 | TBD | Initiating mid-2025 |
| Bipolar Depression | TBD | Phase 3 | TBD | Initiating mid-2025 |

### Recent Data (AES 2025, December 5, 2025)
- **48-month OLE results:**
  - 90.9% monthly seizure reduction
  - 38% achieved â‰¥1 year seizure freedom
  - Strong long-term safety/tolerability profile

---

## 2. Revenue Forecast Model

### Azetukalner Peak Sales Estimates by Indication

| Indication | Peak Sales | PoS | Risk-Adj Peak |
|------------|-----------|-----|---------------|
| Focal Onset Seizures | $1.50B | 55% | $825.0M |
| PGTCS | $500.0M | 50% | $250.0M |
| Major Depression | $2.00B | 35% | $700.0M |
| Bipolar Depression | $800.0M | 35% | $280.0M |
| **Total** | **$4.80B** | -- | **$2.055B** |

### Annual Revenue Projections ($ millions)

| Year | FOS | PGTCS | MDD | BPD | **Total** | Notes |
|------|-----|-------|-----|-----|-----------|-------|
| 2025 | 0.0 | 0.0 | 0.0 | 0.0 | **0.0** | Phase 3 ongoing |
| 2026 | 0.0 | 0.0 | 0.0 | 0.0 | **0.0** | Pre-approval |
| 2027 | 150.0 | 0.0 | 0.0 | 0.0 | **150.0** | FOS launch |
| 2028 | 450.0 | 50.0 | 0.0 | 0.0 | **500.0** | PGTCS launch |
| 2029 | 750.0 | 150.0 | 100.0 | 0.0 | **1,000.0** | MDD launch |
| 2030 | 1,000.0 | 300.0 | 400.0 | 100.0 | **1,800.0** | BPD launch |
| 2031 | 1,200.0 | 400.0 | 800.0 | 250.0 | **2,650.0** | Ramp |
| 2032 | 1,400.0 | 450.0 | 1,200.0 | 400.0 | **3,450.0** | Near peak |
| 2033 | 1,500.0 | 500.0 | 1,600.0 | 600.0 | **4,200.0** | Peak FOS |
| 2034 | 1,450.0 | 480.0 | 1,800.0 | 700.0 | **4,430.0** | Peak MDD |
| 2035 | 1,350.0 | 450.0 | 2,000.0 | 800.0 | **4,600.0** | Peak total |

---

## 3. Detailed Expense & Cash Flow Analysis

### QUARTERLY EXPENSE BREAKDOWN - 2025 ($ thousands)

| Category | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | **FY 2025** |
|----------|---------|---------|---------|---------|-------------|
| **R&D Expenses** | | | | | |
| Clinical Trial Costs | 28,500 | 32,000 | 34,500 | 33,000 | 128,000 |
| - X-TOLE2/X-TOLE3 (FOS) | 12,000 | 13,500 | 14,000 | 13,500 | 53,000 |
| - X-ACKT (PGTCS) | 8,000 | 9,500 | 10,500 | 10,000 | 38,000 |
| - X-NOVA (MDD initiation) | 5,500 | 6,000 | 7,000 | 6,500 | 25,000 |
| - Other trials | 3,000 | 3,000 | 3,000 | 3,000 | 12,000 |
| Personnel (R&D) | 12,500 | 12,800 | 13,200 | 13,500 | 52,000 |
| CMC / Manufacturing | 3,500 | 4,000 | 4,500 | 4,000 | 16,000 |
| Regulatory Affairs | 1,000 | 1,000 | 1,000 | 1,000 | 4,000 |
| **Total R&D** | **45,500** | **49,800** | **53,200** | **51,500** | **200,000** |
| | | | | | |
| **SG&A Expenses** | | | | | |
| Personnel (G&A) | 6,500 | 6,800 | 7,000 | 7,200 | 27,500 |
| Legal & Professional | 2,500 | 2,800 | 3,000 | 3,200 | 11,500 |
| Facilities & IT | 1,500 | 1,500 | 1,500 | 1,500 | 6,000 |
| Insurance & Other | 1,000 | 1,200 | 1,200 | 1,600 | 5,000 |
| **Total SG&A** | **11,500** | **12,300** | **12,700** | **13,500** | **50,000** |
| | | | | | |
| **TOTAL OPERATING EXPENSES** | **57,000** | **62,100** | **65,900** | **65,000** | **250,000** |

### QUARTERLY EXPENSE BREAKDOWN - 2026 ($ thousands)

| Category | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 | **FY 2026** |
|----------|---------|---------|---------|---------|-------------|
| **R&D Expenses** | | | | | |
| Clinical Trial Costs | 30,000 | 28,000 | 24,000 | 20,000 | 102,000 |
| - X-TOLE2/X-TOLE3 (completion) | 10,000 | 8,000 | 4,000 | 2,000 | 24,000 |
| - X-ACKT (ongoing) | 10,000 | 10,000 | 10,000 | 8,000 | 38,000 |
| - X-NOVA (MDD P3) | 7,000 | 7,000 | 7,000 | 7,000 | 28,000 |
| - BPD initiation | 3,000 | 3,000 | 3,000 | 3,000 | 12,000 |
| Personnel (R&D) | 13,500 | 13,800 | 14,000 | 14,200 | 55,500 |
| CMC / Manufacturing | 4,500 | 5,000 | 5,500 | 5,500 | 20,500 |
| Regulatory (NDA prep) | 500 | 500 | 750 | 750 | 2,500 |
| **Total R&D** | **48,500** | **47,300** | **44,250** | **40,450** | **180,500** |
| | | | | | |
| **SG&A Expenses** | | | | | |
| Personnel (G&A) | 8,000 | 9,000 | 10,000 | 11,000 | 38,000 |
| Pre-launch Commercial | 5,000 | 8,000 | 12,000 | 15,000 | 40,000 |
| Legal & Professional | 3,000 | 3,500 | 4,000 | 4,500 | 15,000 |
| Facilities & IT | 1,500 | 1,500 | 2,000 | 2,000 | 7,000 |
| **Total SG&A** | **17,500** | **22,000** | **28,000** | **32,500** | **100,000** |
| | | | | | |
| **TOTAL OPERATING EXPENSES** | **66,000** | **69,300** | **72,250** | **72,950** | **280,500** |

### QUARTERLY EXPENSE BREAKDOWN - 2027 ($ thousands)

| Category | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 | **FY 2027** |
|----------|---------|---------|---------|---------|-------------|
| **R&D Expenses** | | | | | |
| Clinical Trial Costs | 18,000 | 16,000 | 14,000 | 12,000 | 60,000 |
| - X-ACKT (completion) | 6,000 | 4,000 | 2,000 | 0 | 12,000 |
| - X-NOVA (MDD P3) | 8,000 | 8,000 | 8,000 | 8,000 | 32,000 |
| - BPD Phase 3 | 4,000 | 4,000 | 4,000 | 4,000 | 16,000 |
| Personnel (R&D) | 14,500 | 14,500 | 15,000 | 15,000 | 59,000 |
| CMC / Manufacturing | 6,000 | 7,000 | 7,500 | 8,000 | 28,500 |
| Regulatory | 750 | 750 | 500 | 500 | 2,500 |
| **Total R&D** | **39,250** | **38,250** | **37,000** | **35,500** | **150,000** |
| | | | | | |
| **SG&A Expenses** | | | | | |
| Sales Force Build | 15,000 | 20,000 | 25,000 | 30,000 | 90,000 |
| Marketing (launch) | 5,000 | 10,000 | 20,000 | 25,000 | 60,000 |
| Personnel (G&A) | 8,000 | 9,000 | 10,000 | 11,000 | 38,000 |
| Legal & Professional | 2,500 | 2,500 | 3,000 | 4,000 | 12,000 |
| **Total SG&A** | **30,500** | **41,500** | **58,000** | **70,000** | **200,000** |
| | | | | | |
| **TOTAL OPERATING EXPENSES** | **69,750** | **79,750** | **95,000** | **105,500** | **350,000** |

### QUARTERLY EXPENSE BREAKDOWN - 2028-2030 SUMMARY ($ millions)

| Category | FY 2028 | FY 2029 | FY 2030 |
|----------|---------|---------|---------|
| **R&D** | | | |
| Clinical Trials | 40.0 | 30.0 | 40.0 |
| Personnel | 60.0 | 60.0 | 70.0 |
| CMC/Manufacturing | 25.0 | 25.0 | 35.0 |
| Regulatory | 5.0 | 5.0 | 5.0 |
| **Total R&D** | **130.0** | **120.0** | **150.0** |
| | | | |
| **SG&A** | | | |
| Sales Force | 100.0 | 120.0 | 180.0 |
| Marketing | 80.0 | 100.0 | 150.0 |
| Personnel (G&A) | 45.0 | 50.0 | 70.0 |
| Legal/Professional | 15.0 | 18.0 | 30.0 |
| Facilities/Other | 10.0 | 12.0 | 20.0 |
| **Total SG&A** | **250.0** | **300.0** | **450.0** |
| | | | |
| **TOTAL OPEX** | **380.0** | **420.0** | **600.0** |

---

## 4. Cash Flow Analysis - Quarterly Detail

### QUARTERLY CASH FLOW - 2025 ($ thousands)

| Line Item | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | **FY 2025** |
|-----------|---------|---------|---------|---------|-------------|
| **Beginning Cash** | 691,100 | 637,600 | 578,000 | 514,600 | 691,100 |
| | | | | | |
| **Operating Activities** | | | | | |
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Collaboration Income | 2,500 | 2,500 | 2,500 | 2,500 | 10,000 |
| **Total Cash In** | 2,500 | 2,500 | 2,500 | 2,500 | 10,000 |
| | | | | | |
| R&D Expenses | (45,500) | (49,800) | (53,200) | (51,500) | (200,000) |
| SG&A Expenses | (11,500) | (12,300) | (12,700) | (13,500) | (50,000) |
| **Total Cash Out** | (57,000) | (62,100) | (65,900) | (65,000) | (250,000) |
| | | | | | |
| **Net Operating CF** | (54,500) | (59,600) | (63,400) | (62,500) | (240,000) |
| | | | | | |
| **Investing Activities** | | | | | |
| CapEx | (500) | (500) | (500) | (500) | (2,000) |
| **Net Investing CF** | (500) | (500) | (500) | (500) | (2,000) |
| | | | | | |
| **Financing Activities** | | | | | |
| Stock Comp (non-cash adj) | 1,500 | 1,500 | 1,500 | 1,500 | 6,000 |
| Options/Warrants Exercised | 0 | 0 | 0 | 0 | 0 |
| **Net Financing CF** | 1,500 | 1,500 | 1,500 | 1,500 | 6,000 |
| | | | | | |
| **Net Change in Cash** | (53,500) | (58,600) | (62,400) | (61,500) | (236,000) |
| **Ending Cash** | 637,600 | 579,000 | 516,600 | 455,100 | 455,100 |

### QUARTERLY CASH FLOW - 2026 ($ thousands)

| Line Item | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 | **FY 2026** |
|-----------|---------|---------|---------|---------|-------------|
| **Beginning Cash** | 455,100 | 392,600 | 326,800 | 258,050 | 455,100 |
| | | | | | |
| **Operating Activities** | | | | | |
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Collaboration Income | 2,500 | 2,500 | 2,500 | 2,500 | 10,000 |
| **Total Cash In** | 2,500 | 2,500 | 2,500 | 2,500 | 10,000 |
| | | | | | |
| R&D Expenses | (48,500) | (47,300) | (44,250) | (40,450) | (180,500) |
| SG&A Expenses | (17,500) | (22,000) | (28,000) | (32,500) | (100,000) |
| **Total Cash Out** | (66,000) | (69,300) | (72,250) | (72,950) | (280,500) |
| | | | | | |
| **Net Operating CF** | (63,500) | (66,800) | (69,750) | (70,450) | (270,500) |
| | | | | | |
| **Investing Activities** | | | | | |
| CapEx | (500) | (500) | (500) | (500) | (2,000) |
| | | | | | |
| **Financing Activities** | | | | | |
| Stock Comp (non-cash adj) | 1,500 | 1,500 | 1,500 | 1,500 | 6,000 |
| | | | | | |
| **Net Change in Cash** | (62,500) | (65,800) | (68,750) | (69,450) | (266,500) |
| **Ending Cash** | 392,600 | 326,800 | 258,050 | 188,600 | 188,600 |

### QUARTERLY CASH FLOW - 2027 ($ thousands)

| Line Item | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 | **FY 2027** |
|-----------|---------|---------|---------|---------|-------------|
| **Beginning Cash** | 188,600 | 124,850 | 54,600 | 9,600 | 188,600 |
| | | | | | |
| **Operating Activities** | | | | | |
| **Product Revenue** | 0 | 0 | 25,000 | 50,000 | 75,000 |
| - Azetukalner (FOS) | 0 | 0 | 25,000 | 50,000 | 75,000 |
| Gross Margin (85%) | 0 | 0 | 21,250 | 42,500 | 63,750 |
| Collaboration Income | 2,500 | 2,500 | 2,500 | 2,500 | 10,000 |
| **Total Cash In** | 2,500 | 2,500 | 23,750 | 45,000 | 73,750 |
| | | | | | |
| R&D Expenses | (39,250) | (38,250) | (37,000) | (35,500) | (150,000) |
| SG&A Expenses | (30,500) | (41,500) | (58,000) | (70,000) | (200,000) |
| COGS (15% of revenue) | 0 | 0 | (3,750) | (7,500) | (11,250) |
| **Total Cash Out** | (69,750) | (79,750) | (98,750) | (113,000) | (361,250) |
| | | | | | |
| **Net Operating CF** | (67,250) | (77,250) | (75,000) | (68,000) | (287,500) |
| | | | | | |
| **Financing Activities** | | | | | |
| Equity Raise (assumed) | 0 | 0 | 25,000 | 125,000 | 150,000 |
| Stock Comp | 2,000 | 2,000 | 2,000 | 2,000 | 8,000 |
| CapEx | (1,500) | (1,500) | (2,000) | (2,000) | (7,000) |
| | | | | | |
| **Net Change in Cash** | (66,750) | (76,750) | (50,000) | 57,000 | (136,500) |
| **Ending Cash** | 121,850 | 45,100 | (4,900) | 52,100 | 52,100 |

**Note:** 2027 shows a potential cash crunch in Q3. Model assumes $150M equity raise to fund launch.

### ANNUAL CASH FLOW SUMMARY ($ millions)

| Line Item | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|-----------|------|------|------|------|------|------|
| **Beginning Cash** | 691.1 | 455.1 | 188.6 | 52.1 | 196.1 | 801.1 |
| | | | | | | |
| **Revenue** | 0.0 | 0.0 | 75.0 | 425.0 | 850.0 | 1,530.0 |
| Gross Profit (85%) | 0.0 | 0.0 | 63.8 | 361.3 | 722.5 | 1,300.5 |
| Other Income | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 |
| **Total Operating Income** | 10.0 | 10.0 | 73.8 | 371.3 | 732.5 | 1,310.5 |
| | | | | | | |
| R&D Expenses | (200.0) | (180.5) | (150.0) | (130.0) | (120.0) | (150.0) |
| SG&A Expenses | (50.0) | (100.0) | (200.0) | (250.0) | (300.0) | (450.0) |
| **Total OpEx** | (250.0) | (280.5) | (350.0) | (380.0) | (420.0) | (600.0) |
| | | | | | | |
| **Operating Cash Flow** | (240.0) | (270.5) | (276.2) | (8.7) | 312.5 | 710.5 |
| | | | | | | |
| CapEx | (2.0) | (2.0) | (7.0) | (10.0) | (8.0) | (10.0) |
| Equity Financing | 0.0 | 0.0 | 150.0 | 150.0 | 0.0 | 0.0 |
| Stock Comp (non-cash) | 6.0 | 6.0 | 8.0 | 10.0 | 10.0 | 10.0 |
| Milestone Payments | 0.0 | 0.0 | (10.0) | (10.0) | (10.0) | (10.0) |
| | | | | | | |
| **Net Change in Cash** | (236.0) | (266.5) | (135.2) | 131.3 | 304.5 | 700.5 |
| **Ending Cash** | 455.1 | 188.6 | 53.4 | 184.7 | 489.2 | 1,189.7 |

### Key Cash Flow Metrics

| Metric | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|--------|------|------|------|------|------|------|
| Monthly Burn Rate | $19.7M | $22.2M | $23.0M | N/A | N/A | N/A |
| Cash Runway (months) | 35 | 8.5 | 2.3 | 24+ | 24+ | 24+ |
| Operating Margin | N/A | N/A | (369%) | (2%) | 37% | 46% |
| R&D as % Revenue | N/A | N/A | 200% | 31% | 14% | 10% |
| SG&A as % Revenue | N/A | N/A | 267% | 59% | 35% | 29% |

**Break-even Analysis:**
- **Cash flow positive:** Q3 2028
- **Operating income positive:** Q2 2029
- **Cumulative break-even:** Q4 2029

---

## 5. DCF Valuation

### Assumptions
- Discount Rate (WACC): 10%
- Terminal Growth Rate: 2%
- Tax Rate: 21%
- Gross Margin: 85%
- Peak Sales Decline: 5% per year post-peak

### Risk-Adjusted NPV by Indication

| Indication | Unadj NPV | PoS | **rNPV** |
|------------|-----------|-----|----------|
| FOS | $4.50B | 55% | $2.475B |
| PGTCS | $1.20B | 50% | $0.600B |
| MDD | $6.00B | 35% | $2.100B |
| BPD | $2.00B | 35% | $0.700B |
| **Pipeline Total** | **$13.70B** | | **$5.875B** |

### Enterprise Value Calculation

| Component | Value |
|-----------|-------|
| Pipeline rNPV | $5.875B |
| (+) Current Cash | $0.691B |
| (-) Burn to FOS approval (2025-2027) | ($0.742B) |
| (-) Working Capital Reserve | ($0.100B) |
| **Enterprise Value** | **$5.724B** |
| | |
| Shares Outstanding | 77.3M |
| Diluted Shares (options/RSUs) | 82.0M |
| **Implied Share Price (Basic)** | **$74.05** |
| **Implied Share Price (Diluted)** | **$69.80** |
| Current Price | $45.01 |
| **Upside to Fair Value** | **55-65%** |

### Sensitivity Analysis - Fair Value Per Share

**PoS Sensitivity (FOS):**

| FOS PoS | Fair Value | Upside |
|---------|------------|--------|
| 45% | $62.50 | 39% |
| 50% | $66.15 | 47% |
| **55% (Base)** | **$69.80** | **55%** |
| 60% | $73.45 | 63% |
| 65% | $77.10 | 71% |

**Discount Rate Sensitivity:**

| WACC | Fair Value | Upside |
|------|------------|--------|
| 8% | $85.20 | 89% |
| 9% | $77.00 | 71% |
| **10% (Base)** | **$69.80** | **55%** |
| 11% | $63.40 | 41% |
| 12% | $57.80 | 28% |

---

## 6. M&A Scoring Analysis (81/100)

| Factor | Score | Weight | Contribution |
|--------|-------|--------|--------------|
| Pipeline Value | 88 | 15% | 13.2 |
| Clinical Differentiation | 92 | 12% | 11.0 |
| Therapeutic Momentum | 75 | 10% | 7.5 |
| Patent Position | 80 | 8% | 6.4 |
| Cash Runway | 85 | 10% | 8.5 |
| Insider Signals | 70 | 8% | 5.6 |
| Competitive Tension | 78 | 10% | 7.8 |
| Antitrust Risk (inverse) | 95 | 5% | 4.8 |
| Strategic Fit | 85 | 10% | 8.5 |
| Regulatory Pathway | 82 | 5% | 4.1 |
| Pipeline Gap Alignment | 80 | 5% | 4.0 |
| Premium Likelihood | 75 | 2% | 1.5 |
| **TOTAL** | | | **81.4** |

---

## 7. Potential Acquirers

| Acquirer | Fit Score | Rationale | Est. Offer |
|----------|-----------|-----------|------------|
| **UCB** | 88 | Epilepsy specialist, Keppra genericization | $5.5-9B |
| **Jazz Pharma** | 85 | CNS focus, thin pipeline | $5-8B |
| **Lundbeck** | 82 | CNS specialist, MDD synergy | $4.5-7.5B |
| **Biogen** | 78 | CNS pivot, diversification | $5.5-10B |
| **J&J** | 75 | Neuroscience unit | $7-12B |

### Most Likely Acquirer: **UCB**
- Strongest strategic fit (epilepsy focus)
- Faces Keppra generic competition
- Has acquisition capacity (~$3B readily available)
- European buyer avoids some US antitrust scrutiny

---

## 8. Deal Probability Assessment

| Timeframe | Probability |
|-----------|-------------|
| 12 months | 35% |
| 24 months | 55% |

### Key Catalysts That Could Trigger Acquisition

1. **Positive X-TOLE2 data** (Q1 2026) - Highest impact
2. **FDA NDA acceptance** (Q3-Q4 2026)
3. **MDD Phase 3 data** (if positive, could trigger bidding war)

### Estimated Deal Value (Updated for $3.48B Market Cap)

| Scenario | Value | Premium to Current |
|----------|-------|-------------------|
| Floor | $5.2B | 50% |
| Base Case | $7.5B | 115% |
| Bull Case | $12.0B | 245% |

---

## 9. Key Risks

1. **Phase 3 FOS trial failure** - Binary event risk
2. **MDD indication** has lower PoS (35%)
3. **Kv7 safety** - Historical ezogabine retinal issues (different compound)
4. **Commercial execution** - First-time launcher
5. **Competition** from other novel AEDs
6. **Cash runway** - May need $150-300M equity raise pre-profitability

---

## 10. Investment Thesis

### Bull Case
- First-in-class Kv7 mechanism addresses unmet need
- Strong OLE data (90.9% seizure reduction)
- MDD indication could be transformational ($2B+ peak)
- Multiple strategic acquirers interested
- Current valuation ($3.48B) still below rNPV ($5.7B) - 55-65% upside

### Bear Case
- Phase 3 failure risk remains significant
- Depression indications are higher risk (35% PoS)
- No revenue until late 2027 at earliest
- Requires commercial build-out or partner
- Potential dilution from equity raise

---

## 11. Recommendation Summary

### Financial Forecast Summary

| Line Item | Q1 25 | Q2 25 | Q3 25 | Q4 25 | FY 2025 | FY 2026 | FY 2027 | FY 2028 |
|-----------|-------|-------|-------|-------|---------|---------|---------|---------|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | $75M | $425M |
| R&D | $45.5M | $49.8M | $53.2M | $51.5M | $200M | $180M | $150M | $130M |
| SG&A | $11.5M | $12.3M | $12.7M | $13.5M | $50M | $100M | $200M | $250M |
| Net Income | ($54M) | ($60M) | ($63M) | ($63M) | ($240M) | ($271M) | ($287M) | ($9M) |
| Ending Cash | $638M | $579M | $517M | $455M | $455M | $189M | $53M | $185M |

### Key Questions for Review
1. Are the peak sales estimates reasonable by indication?
2. Is the FOS 55% PoS appropriate given OLE data?
3. Should MDD PoS be higher given novel mechanism?
4. Is the 2027 equity raise assumption ($150M) sufficient?
5. Is the $7.5B base case acquisition value realistic?
6. Are the quarterly expense allocations aligned with trial timelines?

---

*Data Sources:*
- [Google Finance - XENE](https://www.google.com/finance/quote/XENE:NASDAQ) - Market data as of Dec 7, 2025
- [Xenon AES 2025 Press Release](https://www.globenewswire.com/news-release/2025/12/05/3200741/33485/en/Xenon-Showcases-New-48-Month-Azetukalner-OLE-Study-Data-in-Epilepsy-at-AES-2025.html)
- [Xenon Pipeline](https://www.xenon-pharma.com/product-pipeline/)
- [SEC Filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001267813)

**Report Version:** 2.0
**Last Updated:** December 7, 2025
